# data[].attributes.body
Vetbiolix is a French biotechnology company

developing innovative veterinary drugs and biologicals derived from recombinant proteins and peptides to improve animal health.

# data[].attributes.custom_properties.0EAQISpI
veterinary therapeutics, recombinant proteins, animal health

# data[].attributes.attachment_link.description
Vetbiolix aims to develop innovative products for treatment and prevention of diseases affecting Pets.

# data[].attributes.body
Vetbiobank is a French biotechnology company

pioneering stem cell–based therapies for veterinary regenerative medicine, with standardized GMP production of mesenchymal stem cells.

# data[].attributes.custom_properties.0EAQISpI
stem cells, veterinary medicine, regenerative therapy

# data[].attributes.attachment_link.title
Vetbiobank mise sur la thérapie cellulaire pour soigner l’arthrose du chien

# data[].attributes.attachment_link.description
[L’instant tech] La start-up lyonnaise Vetbiobank développe une thérapie cellulaire pour soigner l’arthrose du chien. Grâce à une seule...-L’instant Tech

# data[].attributes.body
BioAZ is a French biotechnology company

developing cell-based assays and analytical tools to evaluate the safety and efficacy of biopharmaceutical products.

Keywords:

# data[].attributes.custom_properties.0EAQISpI
bioassays, quality control, biopharma analytics, veterinary science

# data[].attributes.attachment_link.description
Les biotechnologies au service de la santé animale. Des solutions éthiques et durables pour les animaux d'élevage et de compagnie.

# data[].attributes.body
ORINOVA is a French biotechnology company

developing a patented nanomedicine combining chemotherapy and gold nanoparticles to enhance radiotherapy for solid tumours such as glioblastoma.

# data[].attributes.attachment_link.description
ORINOVA développe des nano médicaments en oncologie selon une invention mise au point par deux équipes de recherche de l’université de Franche- Comté. L’innovation ORINOVA repose sur une bithérapie : chimiothérapie et radiothérapie qui agissent simultanément et de façon synergique. Ce médicament est véhiculé dans une nanosphère intelligente qui contient une molécule

# data[].attributes.body
Allozymes is a biotechnology company

applying a proprietary ultra‑high‑throughput microfluidics platform to engineer novel enzymes for sustainable production across pharma, food and chemicals.

# data[].attributes.body
Fungu’it is a French food‑tech company

using solid‑state fermentation of fungi on agricultural by‑products to create 100% natural aromatic and functional ingredients.

Keywords: circular food system, fungal fermentation, natural flavours

# data[].attributes.custom_properties.0EAQISpI
fungal natural products, fermentation, food

# data[].attributes.body
STH Biotech is a French biotechnology company based in Évry-Courcouronnes that develops a proprietary platform called SATIVITRO® to produce rare plant-derived bioactive compounds using engineered hairy root cultures. The technology induces root systems from plant tissues, such as hemp, and grows them in controlled bioreactors to generate high yields of secondary metabolites like triterpenes and alkaloids.

By combining plant biotechnology, metabolic engineering, and bioprocess optimization, STH Biotech provides a sustainable alternative to conventional plant extraction. Its process eliminates the need for soil or light, reduces water and land use, and ensures standardized, traceable production of natural ingredients for cosmetic and health applications.

# data[].attributes.body
Vetophage is a French biotechnology company

specializing in bacteriophage-derived technologies to fight antimicrobial resistance in animal health.

Based near Lyon, it studies and engineers phages and their proteins, such as endolysins,

to develop targeted antibacterial therapies and diagnostic tools.

Its LabMastis S.A kit detects Staphylococcus aureus in dairy cattle using phage-based recognition.

Through molecular biology and protein engineering, Vetophage designs precise, eco-friendly alternatives to antibiotics,

applying the “One Health” approach to link animal, human, and environmental health.

# data[].attributes.custom_properties.0EAQISpI
Animal health, veterinary, bacteriophage 

# data[].attributes.attachment_link.description
Vetophage en lutte contre l’antibiorésistance en santé animale à l’aide de phages et proteines de phages

# data[].attributes.body
Greenphage is a French biotechnology company specializing in the development of bacteriophage-based therapies to combat antibiotic-resistant bacterial infections. Founded as a spin-off from academic research in microbiology and infectious diseases, the company engineers natural bacteriophages—viruses that specifically target and kill bacteria—to create precision antibacterial treatments. Greenphage’s approach aims to overcome antibiotic resistance by exploiting the natural specificity and self-amplifying properties of phages, offering a sustainable alternative to conventional antibiotics.

Their research focuses on therapeutic applications for human and animal health, as well as biocontrol solutions in the food and environmental sectors. By combining molecular biology, phage genomics, and formulation technologies, Greenphage develops safe and highly targeted products designed to preserve the beneficial microbiota while eliminating pathogenic strains. The company’s platform is aligned with the global “One Health” strategy, addressing the growing public health threat of antimicrobial resistance.

# data[].attributes.attachment_link.description
Solutions antibactériennes de précision pour la santé des écosystèmes.

# data[].attributes.body
HTL Biotech is a French company producing pharmaceutical-grade biopolymers through microbial fermentation. Its core products are hyaluronic acid, polynucleotides, and recombinant human collagen III. The firm serves pharmaceutical, medical-device, and cosmetic industries worldwide. Acquired by Montagu Private Equity, HTL has invested heavily in new facilities, including a sterile hyaluronic-acid line opened in 2025 and the collagen platform acquired from Modern Meadow to expand into regenerative medicine and dermal applications.

# data[].attributes.location_name
Biocytex, Chemin de l'Armée d'Afrique, Marseille, France

# data[].attributes.body
BioCytex is a French biotech (now part of the Stago Group) that specializes in developing standardized flow cytometry kits and customized immunomonitoring services. They offer quantitative flow cytometry assays for platelets, leukocytes, red blood cells, and microvesicles, as well as custom services for immunological and biomarker studies for pharma and clinical research.

# data[].attributes.body
Floating Genes is a diagnostic biotech company based in Évry‑Courcouronnes, France. They develop ultra‑sensitive liquid biopsy tools using next‑generation sequencing (NGS) to detect rare mutations in circulating tumor DNA. Their tech includes a reagent kit called “Enhance‑seq” and software for analyzing the NGS data.

# data[].attributes.attachment_link.title
Floating Genes - Annuaire Genopole, Innovation Today, Every Day

# data[].attributes.attachment_link.description
Floating Genes develops diagnostic tools for use in liquid biopsies via the highly sensitive NGS detection of circulating tumor DNA.

# data[].attributes.location_name
PARIS BIOTECH SANTE, Université Paris Cité, Rue du Faubourg Saint-Jacques, Paris, France

# data[].attributes.body
SurgeCare develops an AI‑/multi‑omic platform to fingerprint immune system signatures that predict surgical complications. Their core tech (“Stabl”) sifts through data like CyTOF, transcriptomics, etc., to identify robust, interpretable immune biomarkers. Their first product, PreCyte SSI, is aimed at perioperative risk‑prediction—helping doctors anticipate postoperative complications and tailor care.

# data[].attributes.attachment_link.title
SurgeCare – Transforming Immune Insights into Clinical Impact

# data[].attributes.attachment_link.description
SurgeCare leverages immune profiling and AI to reveal early immune signatures and drive better decisions in surgery, trauma, infection, and beyond.

# data[].attributes.location_name
Xenothera, Rue La Noue Bras de Fer, Nantes, France

# data[].attributes.body
Xenothera is a French biotech company developing treatments based on a glyco-humanized polyclonal antibody (GH-pAb) platform. They have multiple programs across immunology, oncology, viral and bacterial infections. Their lead products include LIS1 (for transplantation), XAV-19 (COVID‑related) and LIS22 (for peripheral T‑cell lymphoma). Their internal GMP biomanufacturing capability supports their pipeline.

# data[].attributes.body
Axol Bioscience develops and supplies human induced pluripotent stem cell (iPSC)‑derived cells and services to support disease modeling, drug discovery, and screening. Their products include ready‑to‑use differentiated cells (e.g. neurons, cardiomyocytes, RPE, etc.), QC tools, banking, gene editing, and custom iPSC lines to enable more human‑relevant in vitro models.

# data[].attributes.attachment_link.description
Home AXOL Bioscience Axol Bioscience, focussed on the supply of human iPSC derived cells for research and drug discovery. Cardiomyocytes and neuronal cells.

# data[].attributes.body
Biose is a Contract Development & Manufacturing Organization (CDMO) that specializes in microbiome therapeutics and next generation probiotics. They provide end‑to‑end services: strain development, process development, GMP production of live bacterial drug substances (both aerobic & anaerobic, GMO or non‑GMO), and finished drug products (capsules, sachets, creams, etc.). It operates a large facility in Aurillac, France, with an R&D / tech‑transfer lab in Boston, USA.

# data[].attributes.attachment_link.description
Your global CDMO for Microbiome Therapeutics

# data[].attributes.body
LiveDrop is a biotech startup from Liège, Belgium, building advanced droplet microfluidic devices for single‑cell assays, 3D cell culture, antibody discovery, and high‑throughput screening. Their platforms include ModaFlow™ and OneFlow™, designed to enable more precise, efficient, and lower‑waste workflows in biology and cell research.

# data[].attributes.attachment_link.title
LiveDrop - Most advanced Droplet Microfluidic Device

# data[].attributes.attachment_link.description
Discover LiveDrop, a specialist in droplet biology, providing cutting-edge microfluidic instruments for high-throughput experiments, including single-cell encapsulation, sorting, and pico-injection. Our integrated solutions, such as OneFlow™ and ModaFlow™, turn months of work into days, offering precision and versatility for your droplet biology research.

# data[].attributes.body
Superbranche develops dendronized magnetic nanoparticles for both diagnostic and therapeutic applications in oncology. Their iron‑oxide nanoparticles are coated with branched (dendrimeric) architecture to enable imaging via MRI and Magnetic Particle Imaging (MPI), and to facilitate therapies like hyperthermia. Their technology aims at early detection, tumor targeting, and treatment monitoring, with an eye toward minimally invasive intratumoral or intravenous administration. They are launching a pilot factory in Sélestat to produce nanomaterials for cancer diagnosis and therapy.

# data[].attributes.attachment_link.description
SUPERBRANCHE : Dendritic Nanoparticles supporting early stage diagnosis and targeted therapy WATCH THE VIDEO ABOUT OUR INNOVATIVE TECHNOLOGY https://www.youtube.com/watch?v=lJ38VeJAFdE SUPERBRANCHE : Nanomedicine as a breakthrough to treat cancer. We bring answers to the following issue: intratumoral injection of nanomaterials implying … Read More

# data[].attributes.body
Algopack produces sustainable, algae-based bioplastics that serve as eco-friendly alternatives to petroleum-derived plastics. Leveraging brown seaweed (including invasive Sargassum), the company transforms marine biomass into two main product lines: a 100% seaweed-based biodegradable polymer (“Algopack®”) and a hybrid “Algoblend®” that combines algae with conventional plastics to reduce fossil content and processing energy. These materials are biodegradable, compostable, and designed to fit existing industrial processes, targeting applications such as office supplies, packaging, horticulture, and logistics.

# data[].attributes.attachment_link.readable_text
Algopack a pour mission de remplacer tout ou partie du plastique issu de pétrole par les Algues, biomasse renouvelable qui capte 960kg de CO2 à la tonne et ne consomme pas d'eau quand elle se développe.

Partant du constat aussi dramatique que terrifiant que 500kg de plastiques finissent chaque seconde dans les océans, et certainement autant dans la nature, ce qui correspond environ à 10% de la production annuelle, Algopack développe des matières ayant un impact positif sur l'environnement issues d'une biomasse renouvelable, n'empiétant pas sur le foncier agricole destiné à nourrir les populations, sans emploi de pesticides, d'insecticides ou fertilisants pour se développer, et l'oxygène diffusé de sa photosynthèse favorise le développement du plancton, base de la vie dans les océans.

Algopack a également développé des formules à base de Sargasses dans le but de trouver une voie de valorisation à ces algues brunes invasives qui s'échouent dans les Caraïbes notamment et dégagent des gaz toxiques pour la santé publique.

Au regard de la gravité des sujets traités par Algopack, tant au niveau de la pollution par les plastiques qu'au niveau de la catastrophe naturelle que représentent les invasions de Sargasses, nous avons mis au point un procédé innovant et unique au monde de valorisation des algues en biomatériaux rigides.
who makes the best https://www.swisswatch.to/ built authority into room table altar. newest cheap real madrid jerseys. aaa+ christiandiorreplica.ru. who makes the best https://www.freepho.to search for pattern stack about the the latest kind. match the ambitions and needs of all the so-called people the globe could be the hunt for https://www.fake-watches.is for sale. www.franckmullerwatches.to are extremely famous swiss.

# data[].attributes.attachment_link.description
Réduisons notre dépendance au plastique. Algopack a pour mission de remplacer tout ou partie du plastique par les algues.

# data[].attributes.body
SeaBeLife is a biotechnology company developing first-in-class small molecules that simultaneously inhibit necroptosis and ferroptosis—two regulated forms of cell death—offering organ-protective therapies for diseases such as dry age-related macular degeneration (AMD), acute liver failure, and acute kidney injury. Their lead candidates, including SBL01 and SBL03, have shown promising in vitro and in vivo efficacy in protecting retinal and organ tissues. SBL03 is being developed as a topical ophthalmic gel for dry AMD, while SBL01 targets acute liver disorders. The platform uniquely blocks both necrotic pathways in tandem to reduce tissue damage and inflammation.

# data[].attributes.attachment_link.title
Seabelife - Sea inspired and life oriented biotech

# data[].attributes.attachment_link.description
SeaBeLife est une société de biotechnologie fondée en 2019 qui développe des petites molécules innovantes ciblant simultanément deux voies majeures de mort cellulaire régulée : la nécroptose et la ferroptose, destinés à répondre à des besoins médicaux majeurs et non couverts, dans des indications aiguës, rares ou chroniques.

# data[].attributes.body
AberActives is a marine biotechnology company developing eco-friendly enzymatic processes to convert algal polysaccharides into high-value ingredients for the cosmetic and nutraceutical markets. They leverage bacterial enzymes to gently break down seaweed biomass, avoiding harsh chemical extraction methods and reducing energy use and environmental impact. Their platform supports the sustainable production of bioactive compounds from both red and green algae.

# data[].attributes.attachment_link.title
AberActives – Biotechnologies marines | Finistère | Bretagne

# data[].attributes.attachment_link.description
Notre laboratoire est situé sur le site du Laber dans les locaux de la station marine de Roscoff, pôle d’excellence mondiale dans la recherche fondamentale sur les algues.

# data[].attributes.body
Algenscribe is a pre-clinical biotechnology company based in Nice, France, that has developed a genome-editing platform aimed at improving human health. The platform enhances the efficiency of homologous recombination and mitigates limitations of nuclease-based gene editing tools. It is being positioned for applications in therapeutics, bioproduction, diagnostics, and research tools. Algenscribe collaborates with academic and industrial partners, including the Max Delbrück Center in Berlin, to accelerate technology development.

# data[].attributes.custom_properties.0EAQISpI
CRISPR, therapy, bioproduction, cell biology

# data[].attributes.attachment_link.title
Algenscribe I Genome Editing I Biotechnology

# data[].attributes.attachment_link.description
AlgenScribe is a biotechnology company developing a genome editing platform to improve human health.

# data[].attributes.body
SE Therapeutics develops self‑entering biologics using a “self-entering domain” (SED), a protein module inspired by naturally evolved bacterial toxins. The SED enables therapeutic proteins—like CRISPR/Cas9 systems, antibodies, and other modalities—to enter cells autonomously via receptor-mediated endocytosis and endosomal escape. By bypassing traditional delivery hurdles, their platform aims to simplify and scale cell and gene therapy manufacturing while enabling previously inaccessible intracellular targets.

# data[].attributes.attachment_link.description
SE Therapeutics is a biotech startup using technology derived from protein domains selected by natural selection to revolutionize cell therapy.

# data[].attributes.body
Core Biogenesis uses plants as biofactories to produce high-value recombinant proteins and growth factors with enhanced stability and efficacy. Their proprietary platform targets peptides and proteins to plant oleosomes, enabling scalable and sustainable bioproduction suitable for applications in life sciences, skincare, cell therapy, and cultivated meat. Their plant-based production process offers eco-friendly, animal‑component‑free manufacturing, greater supply chain security, and cost advantages.

# data[].attributes.custom_properties.0EAQISpI
plant biology, in vitro meat, cell biology

# data[].attributes.attachment_link.description
Biodesigning the Future of Regenerative Medicine & Skincare

# data[].attributes.body
Vital Meat develops cultivated chicken produced via cell-based fermentation to provide sustainable, GMO-free, antibiotic-free protein. Their process starts with robust cells selected from fertilized eggs, scaled in bioreactors, and turned into an ingredient (“VitalChicken”) for food products like hybrid meats. The company has submitted regulatory dossiers in Singapore and the UK and recently hosted a public tasting in Singapore to showcase its cultivated chicken ingredient.

# data[].attributes.location_name
Yangsan-si, Gyeongsangnam-do, Corée du Sud

# data[].attributes.body
Stemden develops small-molecule therapeutics for oral tissue regeneration, focusing on restoring dental structures like dentin, periodontal ligament, and alveolar bone. Their approach aims to enable repair by regeneration for dental health solutions.

# data[].attributes.body
Amporin Pharmaceuticals AG is a Swiss biotech company developing a novel class of orally available, brain-penetrant small molecules targeting amyloid pores—tiny, toxic channels formed by misfolded protein oligomers that disrupt cell membranes. Their therapeutic approach spans three types of compounds: Amporbans (which plug amyloid pores), Amporins (which dissolve them), and Amportacs (which tag them for degradation via the proteasome). The technology aims to halt and potentially reverse neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS by repairing membrane integrity at a molecular level.

# data[].attributes.attachment_link.description
Amporin Pharmaceuticals is developing a new class of pore-targeting therapies for the treatment of protein misfolding diseases.

# data[].attributes.body
Rebrain develops non-invasive neuromodulation devices designed to treat neurological and psychiatric disorders using personalized brain stimulation protocols. Their technology combines real-time EEG monitoring with adaptive stimulation algorithms to modulate brain activity without surgery or implants. Target applications include depression, ADHD, and neurodegenerative diseases, with the goal of offering drug-free alternatives grounded in neuroscience and data.

# data[].attributes.attachment_link.description
Rebrain services provide precise brain targeting for DBS neurosurgery, enhancing patient outcomes in Parkinson’s disease and Essential Tremor treatments

# data[].attributes.body
Mova Life develops microrobotics and microfluidic incubator technologies aimed at optimizing in vitro fertilization (IVF) lab workflows. Their platform combines advanced microfluidics, robotics, and AI to standardize procedures and enhance success rates in assisted reproductive technologies.

# data[].attributes.body
CTI Biotech specializes in producing human 3D cell culture models using primary cells from cancer patients, with a focus on personalized oncology and tissue engineering. Their biobank houses a large collection of tumor-derived cells, which are used to create in vitro models that closely mimic patient tumors. These models support preclinical testing, drug screening, and the development of personalized therapeutic strategies. CTI bridges the gap between patient biology and laboratory research by providing clinically relevant test systems.

# data[].attributes.body
ACS Biotech develops regenerative medicine solutions focused on cartilage repair using a patented 3D chitosan hydrogel matrix that supports chondrocyte implantation with minimally invasive surgery. The company also operates an osteoarticular biobank offering high-quality cartilage-related cell and tissue products along with rigorous quality control for R&D applications. Their platform supports both research and therapeutic development in osteoarticular pathologies.

# data[].attributes.custom_properties.0EAQISpI
Cell culture, 3d culture, Extracellular matrix 

# data[].attributes.body
Inside Therapeutics develops a streamlined nanoparticle formulation platform (TAMARA) for lipid nanoparticles (LNPs) and other nanomedicines. Their microfluidic-based system enables rapid, scalable, and reproducible synthesis—from microliter discovery stages to large-scale production—while ensuring tight control over particle size, polydispersity, and encapsulation efficiency. Their goal is to accelerate nanodrug development and seamless transition from screening to manufacturing.

# data[].attributes.attachment_link.description
We revolutionize nanoparticle manufacturing with intuitive platforms that ease LNP formulation and streamline RNA-LNP vaccines development

# data[].attributes.body
Engreen develops a versatile extracellular vesicle (EV)–based delivery platform, leveraging EVs derived from plants and microalgae to transport therapeutic molecules with precision. Their technology is designed to target both plant and animal pathogens, offering a biologically inspired alternative to traditional treatments—whether in agriculture or veterinary applications. By harnessing EVs’ natural delivery capabilities, Engreen offers a potentially highly specific, environmentally friendly strategy to protect crops and livestock.

# data[].attributes.custom_properties.0EAQISpI
Extracellular vesicles, cell biology, veterinary science, virology 

# data[].attributes.location_name
Solar Foods Oy, Härkälenkki, Vantaa, Finlande

# data[].attributes.body
Solar Foods produces a novel protein called Solein, made from thin air—literally. Using renewable electricity, carbon dioxide, hydrogen, and nitrogen, they grow microbial biomass via fermentation in a process entirely disconnected from agriculture. The result is a sustainable, high-protein powder that can be used in food, drinks, or even space missions. It is an attempt to decouple protein production from land, water, and animals—and replace the cow with a bioreactor.

# data[].attributes.attachment_link.readable_text
For the first time in history, humankind can produce food without burdening our home planet.

Liberating protein production

Food production, as we know it, is entirely dependent on land and weather conditions. Protein production is a massively disproportionate squanderer of the Earth's resources. It's time to enter the era of sustainable food production to liberate our planet from the burdens of agriculture.

Harvesting natural microscopic food

Our unique bioprocess can grow a single microorganism, one of the billions found in nature, into an endless supply of edible food with air, electricity and fermentation. This bioprocess may not be traditional, but it is as natural as the air we breathe.

Solein® - protein out of thin air

Solein is the purest and most sustainable protein in the world. It is nutritionally rich. It can taste and look like anything you use it for. It is unparalleled in its functionality - it can be used in any food, regardless of diet.

A radical impact on the future of food

Food production, as we know it, is entirely dependent on land and weather conditions. Protein production is a massively disproportionate squanderer of the Earth's resources. It's time to enter the era of sustainable food production to liberate our planet from the burdens of agriculture.

From a vision to concrete action

We lead by example. We started the construction of Factory 01 in 2021. We will be ready to produce the world's most sustainable protein in 2024. And this factory is only the first of many to come.

Join the food revolution

Our newsletter "Digesting the Future" keeps you updated on our latest progress and the development of global food production.

"*" indicates required fields

© 2023, Solar Foods, All rights reserved.

# data[].attributes.attachment_link.description
For the first time in history, humankind can produce food without burdening our home planet. Liberating protein production Food production, as we know it, is entirely dependent on land and weather conditions. Protein production is a massively disproportionate squanderer of the Earth's resources.

# data[].attributes.location_name
PULSALYS, Boulevard du 11 Novembre 1918, Villeurbanne, France

# data[].attributes.body
Cellixio develops technologies to minimize shear stress during biomanufacturing processes. Their platform combines automated flow-based systems with proprietary cell-based sensors to detect and reduce mechanical damage caused by pumps, tubing, and other components in cell production workflows. By quantifying how process conditions impact cell viability and function, Cellixio helps optimize bioproduction for higher quality and yield. Their tools are particularly relevant for sensitive mammalian cells used in cell and gene therapies.

# data[].attributes.attachment_link.description
CelliXio is a Deeptech company, expert in exploring and reducing the effects of Shear stress in the fields of Biopharmaceuticals.

# data[].attributes.location_name
Institut de la Vision, Rue Moreau, Paris, France

# data[].attributes.body
Based on a deep-tech spin-off from Sorbonne Université, Institut de la Vision, PSL, and Institut Langevin, Lutèce Dynamics is building a microscopy platform for non‑invasive, live‑cell metabolic imaging. Their innovation—dynamic full‑field optical coherence tomography—captures label‑free 4D visuals of organoids and complex 3D cell cultures while preserving functionality and viability. Compatible with existing microscopes, the module allows longitudinal monitoring of metabolic fluctuations over weeks, significantly reducing sample use and environmental impact. Ideal for drug screening, disease modeling, and personalized medicine.

# data[].attributes.attachment_link.readable_text
We are a team of five experienced researchers in optics and biology from well-know academic institutions (PSL, Inserm, Sorbonne University). By coupling our expertise on non invasive imaging and 2D/3D cell cultures, we propose an innovative solution to rediscover your samples through an amazing color prism reflecting its intrinsic activities.

# data[].attributes.body
MaaT Pharma is harnessing the power of the gut microbiome to restore immune balance, particularly in patients undergoing cancer therapies. Their lead programs involve standardized, donor-derived microbiota therapies delivered either as capsules or enemas—because sometimes saving your immune system starts in your colon. Focused on hematologic cancers and complications like graft-versus-host disease, MaaT takes a pharma-grade approach to an ecosystem that most companies still treat like a black box.

# data[].attributes.body
Fabentech develops polyclonal antibody therapies designed for rapid response to infectious threats—think pandemics, bioterrorism agents, or emerging zoonoses. Their antibodies are produced using equine immunization and purified through a proprietary platform, allowing scalable, ready-to-deploy treatments. While the method might sound old-school, it offers a fast, flexible, and cost-effective approach to neutralizing pathogens when time and supply chains are tight. It is emergency immunology with boots on the ground.

# data[].attributes.attachment_link.description
Fabentech est spécialisée dans le développement et la production de traitements d’urgence contre le bioterrorisme et les maladies infectieuses émergentes.

# data[].attributes.body
Seekyo Therapeutics is a French biotechnology company developing Tumor Activated Therapy™, a platform designed to deliver targeted cancer treatments that are selectively activated within the tumor microenvironment (TME). Their lead candidate, SKY01, is a smart chemotherapy agent that mimics the function of antibody-drug conjugates (ADCs) but operates through enzymatic activation by tumor-specific proteases. This approach enables localized drug release, minimizing systemic toxicity while maximizing therapeutic efficacy. SKY01 has demonstrated superior results in preclinical models of pancreatic, triple-negative breast, lung, and colorectal cancers.

In addition to its therapeutic compound, Seekyo integrates diagnostic and theranostic tools, including companion diagnostics and breath-based VOC markers, to stratify patients and monitor treatment response. The company is in a preclinical stage with validated safety and efficacy in both small and large animal models and is preparing for first-in-human trials. Based in Futuroscope, France, Seekyo is part of the Paris-Saclay Cancer Cluster and aims to position itself as a pioneer in precision oncology through localized activation and patient-tailored treatment.

# data[].attributes.attachment_link.description
The next generation of targeted therapy for solid cancer

# data[].attributes.body
A51 Biotech is a French deep-tech biotechnology startup focused on developing programmable RNA therapeutics for the treatment of complex diseases. Recently emerged from stealth mode, the company presented at the Entrepreneurs First Demo Day in San Francisco, signaling early international ambitions. While specific disease targets, therapeutic platforms, or development stages have not yet been publicly disclosed, A51 Biotech positions itself at the forefront of RNA-based innovation, likely leveraging synthetic biology and computational design. Its low public profile suggests a preclinical stage of development, with future announcements expected as the company matures.

# data[].attributes.attachment_link.description
A51 | 264 followers on LinkedIn. Programmable RNA for multi-target cell modulation

# data[].attributes.location_name
Avenue de Sécheron 15, 1202 Genève, Suisse

# data[].attributes.body
Release Therapeutics is a biotechnology company developing innovative, localized drug delivery platforms designed to release therapeutic agents precisely where and when they are needed. The company’s core technology typically involves stimuli-responsive materials—such as hydrogels or biodegradable carriers—that enable controlled, sustained, or on-demand release of biologics or small molecules. Release Therapeutics aims to enhance the efficacy and reduce systemic side effects of treatments, particularly in areas such as oncology, inflammation, and regenerative medicine.

# data[].attributes.attachment_link.title
Release Tx | Treating genetic disorders without gene therapies

# data[].attributes.attachment_link.description
A best in class, patented, platform technology for the local and targeted delivery of highly potent therapeutic proteins to the CNS and beyond. Release Therapeutics - Treating genetic disorders without gene therapies.

# data[].attributes.location_name
Kheiron Biotech, Pilar, Province de Buenos Aires, Argentine

# data[].attributes.body
Kheiron Biotech is an Argentine biotechnology company specializing in equine cloning and advanced reproductive technologies. It is best known for its work in cloning elite polo horses, using somatic cell nuclear transfer (SCNT) techniques to reproduce high-performance animals with desirable traits. Kheiron integrates genetic preservation, embryo transfer, and veterinary science to support the breeding of champion horses, and it collaborates with top-tier polo teams and breeders globally. The company’s work also raises ongoing discussions on bioethics, animal welfare, and regulation in the context of cloning in sports.

# data[].attributes.attachment_link.description
Equine cloning. We create solutions for breeding programs that give the power to improve performance by preserving and replicating the most valuable equine athletes. We provide our customers with the most precise reproductive technologies to drive performance limits further that ever imagined.

# data[].attributes.body
Osta Therapeutics is a biotechnology company focused on developing targeted therapies to treat osteoarthritis and other degenerative joint diseases. The company leverages insights into cartilage biology and inflammation to create disease-modifying drugs aimed at halting or reversing cartilage degradation, rather than simply managing pain. Their lead candidate therapies involve modulation of specific molecular pathways responsible for joint tissue breakdown, with the goal of preserving joint function and improving patient outcomes.

# data[].attributes.attachment_link.description
OSTA Therapeutics develops smart antibiotics to fight antibiotic resistance

# data[].attributes.body
Colossal is the self-proclaimed “de-extinction company” aiming to bring back the woolly mammoth—not as a museum stunt, but as a climate adaptation tool. Using advanced gene editing, synthetic biology, and stem cell tech, they plan to engineer cold-resistant elephants with mammoth traits. Beyond the spectacle, their work pushes boundaries in conservation genomics and endangered species protection. Whether you call it de-extinction or extreme conservation, Colossal is betting the future of biotech includes a few Ice Age cameos.

# data[].attributes.attachment_link.readable_text
De-Extinction

EXTINCTION IS A
COLOSSAL
PROBLEM FACING
THE WORLD.

And Colossal is the company that's going to fix it.

Combining the science of genetics with the business of discovery, we endeavor to jumpstart nature's ancestral heartbeat. To see the Woolly Mammoth thunder upon tundra once again. To advance the economies of biology and healing through genetics. To make humanity more human. And to reawaken the lost wilds of Earth. So we, and our planet, can breathe easier.

species per year on average are being driven to extinction.

The World Animal Foundation predicts that up to

could become extinct by 2050.

animal and plant
species are threatened
with extinction.

Since 1990, native
species of most land
habitats have FALLEN 20%.

of amphibians

of reef-forming corals

and more than 1/3
of all marine mammals
are THREATENED.

The Solution Is
De-Extinction,

a functional application of advanced gene editing technology aimed at rebuilding the DNA of lost megafauna and other creatures that had a measurably positive impact on our fragile ecosystems.

Find out how we're moving
De-Extinction forward

This is DNA and the
new dawn of genetics.

This is incomprehensibly microscopic.

Yet, this is Colossal - the advanced genetics and biosciences company that's developing the science that will save us, our planet and the species that inhabit it.

MAY PREHISTORY THUNDER FORWARD

BRINGING
BACK THE WOOLLY
MAMMOTH

The Science of Resurrecting
the Woolly Mammoth.

In the minds of many, this creature is gone forever. But not in the minds of our scientists, nor the labs of our company. We're already in the process of the de-extinction of the Woolly Mammoth. Our teams have collected viable DNA samples, and are editing the genes that will allow this wonderful megafauna to once again thunder through the Arctic.

Discover the Science &
Technologies that will revive
the Mammoth +

George Church, Ph.D.
Founder

Ben Lamm
Founder & CEO

Colossal is more than just a genetics and biosciences company.

Founded by Ben Lamm and world-renowned geneticist and serial biotech founder George Church.

Colossal is led by CEO Ben Lamm and anchored by some of the most recognized names in science and industry. Each one driven by their shared vision for a better world.

Scientific Advisory Board

Meet the Colossal Scientific Advisory Board. A team made up of some of the world's most brilliant minds across all the reaches of the scientific community.

Alta Charo, J.D.

Carolyn Bertozzi, Ph.D.

Matthew Liao, Ph.D.

Helen Hobbs, M.D.

FOR A BETTER WORLD

For A
Better World

FOR THE PLANET.
FOR THE ANIMALS.
FOR THE FUTURE.

We are evolving for
the sake of tomorrow.

Human enterprise is responsible for many amazing developments. But many of them came at a cost to our planet and the natural resources the planet has provided for countless millennia. Colossal is leading the charge to restore what has been lost or is at risk of being lost.

# data[].attributes.attachment_link.description
Combining the science of genetics with the business of discovery, we are moving de-extinction forward by resurrecting the Woolly Mammoth through gene editing.

# data[].attributes.location_name
Evotec "Campus Curie", Route d'Espagne, Toulouse, France

# data[].attributes.body
Evotec is a global drug discovery powerhouse offering end-to-end R&D solutions—from target identification to clinical development. They operate as a “biotech-as-a-service” platform, partnering with pharma, biotech, and academia to accelerate therapeutic pipelines. With strengths in small molecules, biologics, iPSC-based disease models, and AI-driven discovery, Evotec blends wet lab depth with computational power. Whether it is neurology, oncology, or infectious disease, Evotec aims to industrialize innovation without becoming just another service provider.

# data[].attributes.attachment_link.title
Together for Medicines That Matter - Evotec

# data[].attributes.attachment_link.description
Evotec is a global biotechnology company committed to advancing drug discovery & development together with our partners for medicines that matter.

# data[].attributes.location_name
22 Boulevard Benoni Goullin, 44200 Nantes

# data[].attributes.body
OSE Immunotherapeutics develops immunotherapies that re-educate the immune system to either attack cancer or restore tolerance in autoimmune diseases. Their portfolio includes checkpoint inhibitors, myeloid-targeting antibodies, and antigen-specific tolerogens—all tailored to modulate immune responses with precision. Whether activating T cells to fight tumors or calming them down in autoimmunity, OSE focuses on tuning the immune system rather than overwhelming it, aiming for long-term control rather than temporary fixes.

# data[].attributes.attachment_link.provider_name
Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

# data[].attributes.attachment_link.title
Ose Immunotherapeutics - Société de biotechnologie intégrée

# data[].attributes.attachment_link.description
Une Société de biotechnologie en phase clinique qui développe des immunothérapies innovantes, en direct ou via des partenariats.

# data[].attributes.body
Nanobiotix is advancing a novel class of radioenhancers that amplify the effect of radiotherapy—without changing the radiation dose. Their lead technology, based on hafnium oxide nanoparticles, is designed to increase local tumor cell destruction while sparing healthy tissue. Delivered directly into the tumor, these particles act like tiny amplifiers that make cancer cells more vulnerable to radiation. The approach targets hard-to-treat solid tumors and aims to make radiotherapy more effective, without altering standard clinical workflows.

# data[].attributes.attachment_link.title
Building new cancer therapies atom by atom | Nanobiotix

# data[].attributes.attachment_link.description
Nanobiotix is a biotechnology company pioneering the discovery, development, manufacture, and commercialization of physics-based nanomedicines

# data[].attributes.location_name
Mnemo Therapeutics, Boulevard Murat, Paris

# data[].attributes.body
Mnemo Therapeutics is developing epigenetically reprogrammed CAR-T cell therapies designed to deliver more durable and potent responses against solid tumors. Their core technology, EnfiniT, enhances the memory and persistence of T cells by rewiring their epigenetic state—essentially giving them a better immune “memory” and longer-lasting function. By combining deep epigenetics, antigen discovery, and cell engineering, Mnemo aims to overcome the traditional limitations of cell therapy in solid cancers.

# data[].attributes.attachment_link.title
Mnemo Tx | Biotech | Paris : Developing a robust, tumour-specific target discovery platform for next generation immunotherapies

# data[].attributes.attachment_link.description
Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body's ability to detect and eradicate cancer.

# data[].attributes.location_name
Eligo bioscience, Avenue de France, Paris

# data[].attributes.body
Eligo Bioscience is pioneering a new class of targeted antimicrobials—“eligobiotics”—that use CRISPR technology to selectively eliminate or modulate harmful bacteria without disturbing the rest of the microbiome. Their platform delivers programmable gene editors via engineered phages, enabling sequence-specific targeting of bacterial DNA. This approach opens the door to precise treatment of infections, antimicrobial resistance, and microbiome-related diseases, offering a powerful alternative to broad-spectrum antibiotics.

# data[].attributes.attachment_link.title
Eligo | In vivo gene editing of the microbiome

# data[].attributes.attachment_link.description
Eligo Bioscience is deploying in vivo gene editing technologies against microbiome targets to address diseases with high unmet needs.

# data[].attributes.location_name
27 Avenue du Général de Gaulle, 94160 Saint-Mandé

# data[].attributes.body
Brink Therapeutics is a Paris-based gene editing startup developing next-generation recombinase enzymes—highly programmable, double-strand-break‑free tools that are safer and more precise than CRISPR‑Cas9. Leveraging directed evolution, AI, and ultra-high-throughput microfluidics, their platform engineers custom recombinases to insert, delete, or modify DNA with surgical accuracy. Targeted initially at improving CAR‑T cell therapies and in vivo gene editing, the company aims to validate multiple therapeutic recombinases and scale access to cell and gene therapy worldwide.

# data[].attributes.location_name
4 Rue Eric de Cromières, 63000 Clermont-Ferrand

# data[].attributes.body
Brenus Pharma develops next-generation off-the-shelf cancer vaccines based on its proprietary STC (Stimulated‑Tumor‑Cell) platform. By exposing allogeneic tumor cells to stressors and haptenation, they create “ghost” cell vaccines aimed at training the immune system to recognize and attack solid tumors—even the cold, hard-to-treat ones. Their lead candidate, STC‑1010, is entering Phase I/IIA trials in metastatic colorectal cancer, with plans to address a broader range of solid tumors. The aim: durable responses and relapse prevention via a proteomics-driven, multi-antigen approach.

# data[].attributes.attachment_link.description
Unlocking the full potential of immuno-oncology by generating first-in-class immunotherapies to initiate a multi-specific in vivo immune response against tumors

# data[].attributes.body
HEMARINA is a biotechnology company leveraging marine biology to address medical and industrial oxygen transport needs. Its flagship innovation is a natural oxygen carrier derived from marine lugworms, offering a universal, cell-free alternative to traditional blood products. Applications range from organ preservation and wound healing to hypoxia-related therapies. HEMARINA’s approach is rooted in biomimicry and responds to critical supply and compatibility issues in transfusion and transplantation medicine.

# data[].attributes.attachment_link.title
HEMARINA - Le 1er transporteur d’oxygène universel à visée thérapeutique - Hemarina

# data[].attributes.attachment_link.description
HEMARINA le 1er transporteur d’oxygène universel à visée thérapeutique En savoir + Vidéo institutionnelle « Scrute la nature, c’est là ... Lire la suite

# data[].attributes.body
INOREVIA develops advanced microfluidic platforms that miniaturize and automate complex molecular biology protocols. Their proprietary droplet-based technology enables precise, low-volume reactions—ideal for working with limited or rare biological samples. By reducing reagent consumption and hands-on time, INOREVIA supports high-sensitivity applications such as single-cell analysis, epigenetics, and precision diagnostics. The platform integrates seamlessly into research and clinical workflows, pushing the boundaries of what is possible with low-input samples.

# data[].attributes.attachment_link.readable_text
THE MAGELIA PLATFORM: An all-in-one game-changing solution

Magelia is a unique multi-OMICs platform, which harnesses our disruptive core technology for high precision magnetic bead handling in low volumes. Magelia outperforms manual protocols in terms of output quality, process efficiency, turnaround time and robustness. Its full integration drastically reduces the need for multiple lab equipments, integrating all the features required to perform most molecular biology protocols. Its full automation ensures high day-to-day reproducibility.

# data[].attributes.body
Evariste is an AI-driven drug discovery company specializing in small-molecule therapeutics that exploit synthetic lethality in oncology. Their Frobenius platform integrates multi-omic data analysis and generative chemistry to identify novel lethal gene pairs and design highly potent, selective inhibitors. Validated targets include PKMYT1 (with lead candidate EVT‑3023) and VRK1 for VRK2‑low tumors, showing CNS penetration in glioblastoma models. By closing the loop between target discovery and lead optimization—achieving ~10× potency gains per ~30 compounds—their approach accelerates preclinical development of precision oncology drugs.

# data[].attributes.attachment_link.title
Evariste | AI Synthetic Lethal Drug Discovery

# data[].attributes.attachment_link.description
Evariste is an AI-enabled drug discovery company that develops small molecule therapeutics for synthetic lethal oncology indications using advanced mathematical modelling and machine learning.

# data[].attributes.location_name
GEG Tech, route 128, Gif-sur-Yvette, France

# data[].attributes.body
GEG Tech is a genetic engineering deeptech firm offering high-performance DNA, RNA, and protein vector platforms for advanced therapies. Founded in 2013 and originating from CNRS and RIKEN research, their technology enables both integrating and non-integrating delivery systems—including lentiviral (Lenti-ONE), RNA-One nanoparticle vectors for gene editing, and VPL-One protein vectors. The innovation lies in balancing efficacy, biosafety, and payload capacity, allowing transient or stable transgene expression with cell-type targeting. Their customizable catalog supports applications from CAR-T and genome editing to vaccines and disease models. With ISO-certified BSL-2/3 labs at Paris-Saclay, GEG Tech bridges vector design and production, empowering precise, scalable genetic interventions.

# data[].attributes.custom_properties.0EAQISpI
Heathery, car-t, cell culture, bioproduction 

# data[].attributes.attachment_link.title
Genetic Engineering Innovations - DNA-RNA Platforms GEG Tech

# data[].attributes.attachment_link.description
GEG Tech establishes research programs using its platform with academic and industrial groups for fundamental research and early-stage therapeutic development.

# data[].attributes.location_name
Université Paris Cité, Faculté de Santé, 24 Rue du Faubourg Saint-Jacques, 75014 Paris, France

# data[].attributes.body
Kyron.bio engineers advanced glycan‑engineering platforms to enhance therapeutic protein performance. Their innovation enables precise, programmable control of glycosylation patterns on biologics—using engineered cell lines to produce antibodies with consistent sugar profiles, improving safety, efficacy, and batch-to-batch stability. Validated to achieve >97% glycan uniformity and scalable via mammalian cell factories, the technology addresses a critical bottleneck in biopharmaceutical manufacturing, unlocking next-generation medicines with optimized immune compatibility and function.

# data[].attributes.body
Seekyo Therapeutics develops a novel “Tumor Activated Therapy™” (TAT) platform for solid tumors. Their proprietary SKY molecular system combines a targeting unit and cleavable linker that exploits tumor microenvironment-specific proteins to activate cytotoxic payloads only within the tumor niche. This mechanism bypasses tumor cell heterogeneity and avoids dependence on surface markers. Lead candidate SKY01 has demonstrated strong efficacy and safety in small- and large-animal models across multiple cancer types—including pancreatic, TNBC, lung, and colorectal—and benefits from high plasmatic stability and favorable pharmacokinetics. Seekyo’s innovation resides in a modular, enzyme-triggered drug delivery system designed to convert tumors into self-targeting agents, offering a precision approach to chemotherapy with potential reduced off-target toxicity.

# data[].attributes.attachment_link.description
The next generation of targeted therapy for solid cancer

# data[].attributes.location_name
Stem Genomics, Rue de la Valsière, Grabels, France

# data[].attributes.body
Stem Genomics offers next-generation genomic quality control tools for human stem cell research and cell therapy manufacturing. Their proprietary assays—including digital PCR-based iCS-digital™ kits, G-banding, NGS panels, STR profiling, and mycoplasma testing—provide rapid, sensitive, and cell-type-specific detection of chromosomal abnormalities, cell identity, pluripotency, and sterility. Rooted in ISSCR standards and ISO 9001 certification, the platform enables streamlined, high-throughput monitoring of genomic integrity in hPSCs, MSCs, and custom cell lines. The innovation lies in integrating precision diagnostics into scalable workflows, allowing researchers and manufacturers to detect genetic drift early—ensuring reproducible, safe, and regulatory-compliant cell products.

# data[].attributes.location_name
120 Impasse Jeanne Barret, 31320 Auzeville-Tolosane, France

# data[].attributes.body
Micropep develops sustainable, peptide-based biocontrol and biostimulation solutions for agriculture. Their proprietary Krisalix™ platform combines AI-driven discovery, micropeptide synthesis, and optimized formulation to regulate plant gene expression—enhancing stress resistance, growth, and pathogen defense without altering DNA. Originating from CNRS-UT3 research in 2016, the company delivers natural micropeptides that function as precise, eco-friendly alternatives to conventional agrochemicals. Their modular discovery-to-field pipeline supports scalable production and field deployability, offering farmers molecular precision with minimal ecological footprint.

# data[].attributes.custom_properties.0EAQISpI
Environment, agriculture, AI, biocontrol 

# data[].attributes.body
Goliver Therapeutics is a regenerative medicine startup developing off-the-shelf, pluripotent stem cell-derived hepatocyte therapies for liver failure. Their lead product, GLTX-001, consists of cryopreserved hepatic progenitor cells that can be injected to support liver repair without a graft. Leveraging their iMillenium™ platform, they manufacture large-scale, GMP-ready cell batches, enabling immediate use at the patient’s bedside. Preclinical studies show potent paracrine-driven liver regeneration, and the GOCLINICALS program recently received regulatory support to transition GLTX-001 into first-in-human trials. Innovatively, Goliver merges scalable pluripotent stem cell biomanufacturing with bedside-ready liver therapeutics—offering a practical alternative to transplantation.

# data[].attributes.attachment_link.provider_name
Goliver Therapeutics - Développement de Médicaments

# data[].attributes.attachment_link.title
ACCUEIL - Goliver Therapeutics - Développement de Médicaments

# data[].attributes.attachment_link.description
Goliver Therapeutics est une spin-off de CRTI UMR1064, ITUN, CHU de Nantes, spécialisée dans le développement de Médicaments de Thérapie Innovantes (MTI).

# data[].attributes.body
Brenus Pharma develops an off-the-shelf, allogeneic cellular immunotherapy platform—called STC™ (Stimulated Tumor Cells)—designed to prevent solid tumor recurrence. Their technology uses proteomic profiling to stimulate and harvest tumor-ghost cells that capture tumor heterogeneity and resistance mechanisms, aiming to “educate” the immune system to anticipate and attack evolving cancer cells. Preclinical work in colorectal cancer models shows robust activation of CD8⁺ infiltration and efficacy even in PD-1 resistant tumors; the lead asset STC‑1010 is now advancing into first-in-human trials. Developed with a scalable GMP-ready pipeline and multi-omic validation, the platform offers a biologically precise, modular approach to immunotherapy—trading personalized autologous complexity for standardized, broadly applicable immune education.

# data[].attributes.attachment_link.description
Unlocking the full potential of immuno-oncology by generating first-in-class immunotherapies to initiate a multi-specific in vivo immune response against tumors

# data[].attributes.location_name
11 Rue Gutenberg 9, 63100 Clermont-Ferrand, France

# data[].attributes.body
Afyren is a green chemistry innovator transforming non-food biomass into 100% biobased carboxylic acids via a proprietary, biomimetic fermentation process. Their platform produces a range of high-value acids—acetic, propionic, butyric, valeric, and more—under zero-waste, low-carbon conditions, delivering sustainable drop-in replacements for petrochemical counterparts. The Afyren Neoxy biorefinery in Carling-Saint-Avold marks their transition to continuous industrial production, validating scalability and process control. Scientifically, the innovation lies in orchestrating natural microbial consortia without genetic modification, achieving structural purity and environmental efficiency. Afyren positions itself at the nexus of circular bioeconomy and industrial biotech, offering scalable, chemically versatile, and eco-friendly feedstocks for chemicals, materials, nutrition, and life sciences.

# data[].attributes.custom_properties.0EAQISpI
Bioproduction, microbiology , food, environment

# data[].attributes.attachment_link.title
Afyren : des alternatives à la pétrochimie - Découvrez la Greentech

# data[].attributes.attachment_link.description
Les réserves accessibles de pétroles ont mis 600 millions d’années à se former, et 200 ans à être presque épuisées. En pomper va être de plus en plus difficile et, si c’est probablement une bonne chose qu’on arrête de l’utiliser comme carburant, il est aussi vrai que c’est une matière première importante dans de nombreuses ... Afyren : des alternatives à la pétrochimie

# data[].attributes.location_name
IPGG - Institut Pierre-Gilles de Gennes, Rue Jean Calvin, Paris, France

# data[].attributes.body
Cyprio is a biotech spin-off from ESPCI Paris, specializing in physiologically relevant 3D liver models using their proprietary BioPearl technology. They fabricate uniform, liquid-core hepatocyte spheroids (HepatoPearls) at scale, designed for high-throughput applications including drug metabolism, chronic toxicity, and disease modeling. Innovatively bridging physicochemistry and liver biology, Cyprio’s platform delivers reproducible, microtissue constructs compatible with standard screening pipelines—offering more predictive, human-relevant in vitro liver models without the variability of traditional monolayer cultures.

# data[].attributes.custom_properties.0EAQISpI
Preclinical, 3d, organoids , cell culture 

# data[].attributes.attachment_link.description
Fondée en 1882 à Paris, l’ESPCI Paris est une grande école d’ingénieurs qui forme, par la recherche, en physique, chimie et biologie.

# data[].attributes.location_name
231 Rue Saint-Honoré, 75001 Paris, France

# data[].attributes.body
MesoBioTech is a microfluidics spin‑off from ENS Paris, specializing in modular, plug‑and‑play organ‑on‑chip and stem‑cell culture devices. Their product ecosystem includes integrated chips, flow controllers, and nanofiber-based culture patches for applications ranging from automated stem-cell assays to tissue modeling. A key innovation is their scalable, mass‑fabricated yet customizable platform: chips are monolithic but adaptable, and culture patches mimic natural extracellular matrices. This enables high reproducibility, streamlined workflows, and rapid adoption by researchers without deep engineering skills. In essence, they bridge academic microfluidics and industrial usability for biomedical modeling.

# data[].attributes.custom_properties.0EAQISpI
Microfluidics, cell culture , 3d , organ on chip

# data[].attributes.location_name
EVerZom, Rue des Saints-Pères, Paris, France

# data[].attributes.body
EverZom is a pioneering exosome biotech developing regenerative therapeutics from mesenchymal stem cell–derived extracellular vesicles. Their proprietary platform spans optimized cell sourcing, scalable exosome production, molecular loading, and formulation. Key lead programs include EViv for digestive tissue repair (e.g., Crohn’s fistula) and EVerGel for organ regeneration (liver, kidney), with preclinical data showing accelerated healing and reduced inflammation and fibrosis. Their modular pipeline aims to treat high-unmet-need indications using off-the-shelf, cell-free vesicles that combine the potency of cell therapy with improved safety, stability, and manufacturing control. The company is recognized for its deep-tech rigor and translational focus.

# data[].attributes.attachment_link.description
EVerZom is an exosome biotech company developing exosome therapeutics in digestive tissue healing, fistula and organ regeneration.

# data[].attributes.location_name
Impasse de l'Aigas, Tassin-la-Demi-Lune, France

# data[].attributes.body
Sirius NeoSight develops a platform for the detection and isolation of circulating tumor cells (CTCs) based on measuring cell membrane fluidity. Leveraging a proprietary fluorescent molecule, their method quantifies a fluidity index that is cell-type agnostic, enabling universal capture of CTCs regardless of tissue origin. Born from nearly a decade of research at Lyon’s CRCL and CNRS, the technology has demonstrated proof-of-concept in vitro, in vivo, and in patient samples. Current deployment spans multiple clinical trials in collaboration with Hospices Civils de Lyon and the Léon Bérard Centre. By enabling early cancer recurrence detection, therapy resistance monitoring, and personalized treatment stratification, Sirius offers a real-time, label-free liquid biopsy tool with strong translational potential.

# data[].attributes.attachment_link.title
Sirius NeoSight - New view for cancer therapeutic

# data[].attributes.attachment_link.description
Développement d’un marqueur universel des cellules tumorales circulantes pour la détection, le suivi et l’orientation thérapeutique en oncologie Sirius NeoSight développe une technologie de mesure de fluidité membranaire capable de discriminer et purifier de façon universelle et hautement performante les Cellules Tumorales Circulantes (CTCs) présentes dans la circulation sanguine. La technologie de Sirius ambitionne de […]

# data[].attributes.location_name
Génopole, Rue Henri Auguste Desbruères, Évry-Courcouronnes, France

# data[].attributes.body
BioHive offers customizable, human iPSC-derived skin organoids as advanced in vitro models for dermatological R&D. Their platform integrates epidermis, dermis, hair follicles, neurons, and adipocytes to replicate skin complexity—supporting robust toxicity and efficacy assays in pharma and cosmetic contexts. As a modular biobank, they enable pathology-specific models tailored to client needs, enhancing reproducibility and reducing dependence on animal testing. Born from academic innovation, BioHive bridges developmental biology and industrial screening with precision, cellular fidelity, and tailored utility for compound evaluation.

# data[].attributes.custom_properties.0EAQISpI
Ips, organoids, cell culture , 3d, organoids 

# data[].attributes.attachment_link.description
Revolutionize your biomedical research with BioHive’s custom-engineered skin organoids.

# data[].attributes.body
Pili is a deeptech company producing biobased dyes and pigments via a hybrid fermentation–chemistry platform. They use renewable biomass (e.g., agricultural co-products) and engineered microbial cell factories to generate high-performance colorants like indigo, then apply green chemistry to convert these intermediates into pigments suitable for textiles, coatings, and plastics. By combining industrial fermentation with low-waste organic synthesis, Pili offers decarbonized color solutions that meet industry standards for tint strength, purity, and durability. Their innovation lies in delivering scalable, fossil-free dyes with traceable supply chains—helping industries reduce chemical waste and CO₂ emissions while avoiding the limitations of plant-derived or petrochemical counterparts.

# data[].attributes.body
NETRI develops a compartmentalized microelectrode-array (MEA) organ-on-chip platform that leverages human neurons as living biosensors. Their NeuroFluidics™ 96-well system supports high-throughput, compartmentalized electrophysiological recordings under controlled stimulation, enabling quantification of neurotoxicity, drug efficacy, and dermatological responses. Coupled with AI-powered signature libraries and predictive analytics, the platform translates complex neuronal signals into clinically relevant endpoints. Originating in 2018, NETRI offers scalable, neuron-based smart assays ideal for pharma, cosmetics, and environmental safety testing—bridging preclinical data to human outcomes with cellular precision.

# data[].attributes.attachment_link.description
Enhancing human healththrough the discriminating powerof the nervous system. THESE NEURONS ARE BIODIGITAL SENSORS THEY TRANSLATE PRE-CLINICAL DATAINTO CLINICAL OUTCOMES : WILL MY CANCER TREATMENT HAVE SIDE EFFECTS?IS MY COMPOUND NEUROTOXIC?WILL MY CREAM ITCH?

# data[].attributes.location_name
14/16 Boulevard Poissonnière, 75009 Paris, France

# data[].attributes.body
Owkin is an AI-driven biotech company that combines federated learning with multimodal patient data to accelerate drug discovery, de-risk clinical trials, and develop diagnostic tools. Their flagship platform, Owkin K Navigator, uses cutting-edge agentic AI—integrating spatial omics, imaging, and clinical records—to uncover biomarkers and predict patient outcomes. The federated architecture enables secure collaboration with academic and pharma partners without data pooling. With validated AI diagnostics (e.g., colorectal cancer MSI screening and breast cancer relapse risk), the company bridges advanced AI and translational medicine, offering scalable, privacy-preserving tools for precision healthcare.

# data[].attributes.location_name
24 Rue Jean Baldassini batiment b, 69007 Lyon, France

# data[].attributes.body
Fabentech is a French biopharmaceutical SME focused on rapid-response immunotherapies against high-priority biological threats—pandemic viruses, toxins, and bioterror agents. Their core innovation, FabShield®, leverages a polyclonal antibody fragment platform (F(ab')₂), capable of neutralizing evolving pathogens through broad-spectrum binding. The company has advanced products targeting H5N1, Ebola, and CBRN toxins, with proven preclinical efficacy and compassionate-use cases. Fabentech combines high-throughput antibody screening with GMP-ready production to deliver adaptable countermeasures, offering a biology-driven, scalable defense toolkit for global health security.

# data[].attributes.location_name
Rue du Professeur Joseph Anglada, Montpellier, France

# data[].attributes.body
Cilcare is a biotech specialized in auditory science, developing technologies and therapies for hearing disorders—particularly cochlear synaptopathy, tinnitus, and hidden hearing loss. They offer three integrated pillars: advanced preclinical models (in vitro/ex vivo/in vivo), auditory analytics using AI to generate digital auditory biomarkers, and therapeutic candidates including CIL001, currently entering Phase IIa. Originating in 2014, the company operates in Montpellier, Boston, and Paris, and collaborates with partners like CBSET and Shionogi. Their innovation lies in combining robust, translational auditory models with machine learning to improve diagnosis, patient stratification, and treatment precision—positioning Cilcare at the intersection of auditory R&D, AI-driven biomarkers, and targeted therapeutics.

# data[].attributes.custom_properties.0EAQISpI
3d, cell culture, clinical , organoids, biofabrication 

# data[].attributes.location_name
30 Rue de Campo-Formio, 75013 Paris, France

# data[].attributes.body
Alvéole is a bioengineering company that provides photopatterning and microfabrication tools to control cellular microenvironments in vitro. Their core product, PRIMO, uses maskless, contactless UV micromirror-based photolithography to spatially pattern proteins and microstructures on substrates—without disrupting standard microscopy workflows. This enables precise control over cell adhesion, migration, mechanobiology, and tissue architecture at subcellular resolution. Their add-on fluidics system, NOMOS, automates rinsing protocols, enhancing reproducibility. Founded by CNRS researchers, Alvéole translates sophisticated microengineering into user-friendly instruments, enabling researchers to create biomimetic, reproducible cell models with minimal protocol variance.

# data[].attributes.location_name
Rue ZAE Ecopole, 33190 Loupiac-de-la-Réole, France

# data[].attributes.body
Toopi Organics valorise les déchets liquides en cultivant des biostimulants agricoles à partir d'urine humaine. Leur processus consiste à collecter l'urine dans des lieux publics, la filtrer et la fermenter pour produire des microorganismes capables d’améliorer la nutrition des plantes, notamment le phosphore, ou de lutter contre le stress hydrique. Innovants en biologie et microbiologie environnementale, ils proposent des solutions circulaires pour l’agriculture durable, notamment dans les domaines viticole, maraîcher et bio. La technologie repose sur une fermentation contrôlée, optimisée pour la biodisponibilité des nutriments, et constitue une alternative scientifique et éthique aux fertilisants chimiques, avec un modèle prêt à l’emploi pour les exploitations professionnelles.

# data[].attributes.location_name
The Center for Novel Therapeutics, Athena Circle, La Jolla, CA 92037, USA

# data[].attributes.body
Trestle Biotherapeutics is engineering implantable, stem cell-based kidney tissues to restore renal function in end-stage renal disease. Their preclinical platform combines 3D biofabrication, automated bioprinting, and pluripotent stem cell differentiation to produce vascularized renal organoids. Designed for surgical implantation, these tissues aim to reduce or eliminate dialysis dependence and delay transplant needs. Technologically, they bridge advanced bioprinting workflows with scalable cell manufacturing and vascular integration—highlighted by a recent collaboration with Humacyte to vascularize kidney constructs using off-the-shelf acellular vessels. A scientifically ambitious, translational pivot toward functional bioengineered organs.

# data[].attributes.body
Biodol Therapeutics targets chronic neuropathic pain by developing first-in-class small-molecule inhibitors of the FLT3 receptor. Their compounds—negative allosteric modulators—block FLT3 activity extracellularly, effectively reversing neuropathic pain and enhancing opioid efficacy without inducing tolerance or hyperalgesia. Lead candidate BDT272, currently in Phase I trials, demonstrates oral bioavailability and strong preclinical efficacy metrics. Originating from academic insights into FLT3’s pivotal role in pain and reinforced by patented innovation in compound design, Biodol offers a biology-driven, mechanistically novel approach to pain management that departs from traditional analgesics.

# data[].attributes.attachment_link.readable_text
2 June 2025
BIODOL Therapeutics will be attending BIO International Convention 2025, Boston, USA, June 16-19.
Contact us via a meeting request on the One-on-One partnering platform!

26 May 2025
BIODOL Therapeutics Reports on Ongoing Phase 1 Clinical Study in Healthy Volunteers for BDT272.

14 January 2025
BIODOL Therapeutics and KYORIN Pharmaceutical announce strategic Option Agreement for license to BDT272, a first-in-class treatment for pain.

13 November 2024
Our latest publication in Nature Communications 2024:"FLT3 signaling inhibition abrogates opioid tolerance and hyperalgesia while preserving analgesia".

23 September 2024
BIODOL Therapeutics will be attending Bio-Europe.
Join us in Stockholm, November 4-6!

21 May 2024
Biodol Therapeutics gathers €7 million to progress its oral, next-generation pain therapy into the clinic.

1 September 2023
BIODOL Therapeutics will be attending Bio-Europe.
Join us in Munich, November 6-8!

22 May 2023
BIODOL Therapeutics will be attending BIO 2023, Boston, USA, June 3-8.
Contact us via a meeting request on the One-on-One partnering platform!

6 April 2023
BIODOL Therapeutics will be attending Bio€quity.
Join us in Dublin, May 14-16!

15 February 2023
BIODOL Therapeutics will be attending Bio-Europe Spring.
Join us in Basel, March 20-22!

30 January 2023
We are pleased to share our new study on pain chronification in Progress in Neurobiology.

17 October 2022
BIODOL Therapeutics will be attending Bio-Europe.
Join us in Leipzig, October 24-26!

7 September 2022
Our colleague Cyril RIVAT from the Institut for Neurosciences of Montpellier will present our collaborative results at the IASP 2022 World Congress on Pain in Toronto, Canada, 19-23 September 2022.

31 August 2022
Biodol Therapeutics announces the nomination of its first PreClinical Candidate as a next-generation stand-alone therapy for Neuropathic Pain.

6 May 2022
Our colleague Cyril RIVAT from the Institut for Neurosciences of Montpellier will present our collaborative results at the Pain Mechanisms and Therapeutics Conference in Verona, Italy, 29 May - 3 june 2022.

21 April 2022
BIODOL Therapeutics will be attending Bio€quity.
Join us in Milan, May 16-18!

4 March 2022
BIODOL Therapeutics will be attending BIO-Europe Spring 2022 delivered digitally, March 28-31.
Contact us via a meeting request on the One-on-One partnering platform!

25 September 2021
BIODOL Therapeutics will be attending BIO-Europe 2021 delivered digitally, October 25-27.
Contact us via a meeting request on the One-on-One partnering platform!

4 October 2020
BIODOL Therapeutics will be attending BIO-Europe 2020 delivered digitally, October 26-29.
Contact us via a meeting request on the One-on-One partnering platform!

31 August 2020
BIODOL Therapeutics receives €4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures.

5 February 2020
BIODOL Therapeutics will be attending BIO-Europe Spring 2020 delivered digitally, March 23-27.
Contact us via a meeting request on the One-on-One partnering platform!

3 June 2019
BIODOL Therapeutics, has been selected as one of the TOP TEN French Biotech!
Meet us on Monday June 3, 2019, at Temple University, Philadelphia, USA - VIP event

10 April 2019
BIODOL Therapeutics will be attending BIO 2019, Philadelphia, USA, June 2-6.
Contact us via a meeting request on the One-on-One partnering platform!

20 February 2019
BIODOL Therapeutics will be attending BIO-Europe Spring 2019 Vienna, Austria on March 25-27.
Contact us via a meeting request on the BIO-Partnering site!

23 October 2018
BIODOL Therapeutics will be attending BIOFIT 2018 Lille, France on December 4-5.
Contact us via a meeting request on the BIO-Partnering site!

28 August 2018
BIODOL Therapeutics obtains a grant from the French National Research Agency.
Over the course of 3 years, and with a global budget of more than 1.5 m€, BIODOL THERAPEUTICS, with its historical academic partners (Laboratory of Therapeutic Innovation and Institute for Neurosciences of Montpellier), will develop its anti-FLT3 NCEs program.

18 May 2018
Why don't meet in BIO-BOSTON 2018 which our CSO Pr. Pierre Sokoloff will attend?
Join us via a " meeting request " on the BIO-Partnering site to know more about BIODOL's technology and strategy.

12 April 2018
BIODOL Therapeutics has been selected by Challenges as one of the "100 start-ups where to invest in 2018". See more.

13 March 2018
The French National Institute for Health and Medical Research (INSERM) and the French National Center for Scientific Research (CNRS) announce that its scientists working with Biodol Therapeutics made the discovery of a novel mechanism for treating chronic pain. See more.

12 March 2018
Nature Communications publishes an article, in which Biodol Therapeutics takes a part, describing the validation of FLT3 as a target to treat neuropathic pain. The article also reports the discovery of BDT001 as an extracellular inhibitor and its properties to reverse neuropathic pain symptoms in animal models. See more.

14 February 2018
Following its nomination as part of 40 highly-selected French start-ups for the Tech Tour 2018 "France Tech Transfer Invest - FTTI" (13-14 February 2018 in Paris), we are proud to announce that BIODOL THERAPEUTICS has been selected as part of the European Venture Contest Finalists of this event. See more.

26 January 2018
Biodol Therapeutics is one of the 40 start-ups selected to participate in the 2018 France Tech Tour taking place in Paris on February 13-14th. See more.

17 December 2017
Biodol Therapeutics has been granted for funding by the French Region Occitanie, to cover 60% of R&D costs to develop its anti-FLT3 program.

15 February 2017
BIODOL Therapeutics will be attending BIO-Europe Spring 2017 Barcelona, Spain on March 20-22.
Contact us via a meeting request on the BIO-Partnering site!

6 July 2016
Biodol Therapeutics is awarded at the 2016 ILab/BPI France contest.

# data[].attributes.attachment_link.description
2 June 2025 BIODOL Therapeutics will be attending BIO International Convention 2025, Boston, USA, June 16-19. Contact us via a meeting request on the One-on-One partnering platform! 26 May 2025 BIODOL Therapeutics Reports on Ongoing Phase 1 Clinical Study in Healthy Volunteers for BDT272.

# data[].attributes.body
Prometheus Life Technologies is a Swiss space biotech spin-out from the University of Zurich that cultures fully self-organizing human tissue organoids in microgravity. By flying stem-cell constructs to the ISS, they harness true zero-g conditions to produce homogeneous, scaffold-free 3D organoids—superior in differentiation and reproducibility compared to terrestrial models. Having completed two ISS missions, they now operate their first EU office in Strasbourg’s International Space University incubator, coordinating space missions and future R&D collaborations. The innovation: leveraging authentic microgravity to create high-quality human tissues at scale, positioning themselves as a provider of next-gen biological substrates for drug discovery, disease modeling, and regenerative medicine.

# data[].attributes.body
Okomera offers OCentra™, a benchtop, automated microfluidic platform for high-throughput screening of patient-derived tumor organoids. By combining miniaturized droplet-based assays with AI-enabled imaging and analysis, it enables precision drug testing on up to 1,000 organoids and 100 experimental conditions per run. Originally stemming from École Polytechnique and Pasteur Institute expertise in droplet microfluidics, the technology allows multiplexed co-cultures (e.g. immune-tumor) and supports CRISPR, T-cell, and cytotoxicity assays. It delivers rapid, scalable, and biologically relevant data for oncology R&D, enhancing preclinical predictivity and reducing reliance on animal models.

# data[].attributes.custom_properties.0EAQISpI
organ-on-chip, organoids, microfluidics, cell culture, AI

# data[].attributes.attachment_link.title
Okomera - The Engine for High Impact Drug Discovery

# data[].attributes.attachment_link.description
Okomera is developing an innovative approach to accelerate the development of personalized cancer treatments. The technology allows to test a panel of potential therapies (chemotherapy, immunotherapy, cell therapy, combined therapies) on the patient’s cells derived from tumor biopsy and cultured in 3D-spheroids on microfluidic chips.

# data[].attributes.body
Alga Biologics engineers a microalgae-based bioproduction platform to produce recombinant proteins—especially therapeutic antibodies—with precise human-like glycosylation. Their patented microalgal cell lines offer stable, animal-component-free cultivation, reduced contamination risk, and up to 70% lower production costs compared to mammalian systems. The technology has been validated at 200 L scale, demonstrating scalability and applicability to health, animal, and cosmetic markets. Originating from over a decade of academic research at Université de Rouen, the platform merges environmental sustainability with industrial-grade biopharmaceutical manufacturing.

# data[].attributes.attachment_link.title
Alga Biologics - Commencez Votre Production Aujourd’hui

# data[].attributes.attachment_link.description
Inspirés par les océans et les microalgues marines, sources de vie, nous avons créé une plateforme révolutionnaire pour la production de protéines recombinantes. Notre technologie brevetée dépasse les limitations des méthodes traditionnelles, offrant une solution durable et respectueuse de l’environnement.

# data[].attributes.body
Biomede is a French environmental biotech company specializing in the phytoextraction of heavy metals from contaminated soils. They deploy tailored mixes of hyperaccumulating plants—optimized over years of R&D—for targeted removal of metals like copper, lead, nickel, and cadmium. The process starts with a diagnostic assessment of soil contamination, followed by seed distribution, plant cultivation, and subsequent harvesting. Extracted metals are reclaimed and valorized, closing the loop in a circular-economy approach. Biomede’s solution offers a scalable, sustainable alternative to conventional soil remediation, especially suited to agriculture and viticulture, combining microbiology, seed selection, and environmental engineering into a turnkey bio-based cleanup platform.

# data[].attributes.location_name
Clean Cells SAS, rue Nicolas Sadi Carnot, Montaigu-Vendée, France

# data[].attributes.body
Clean Cells provides GMP-compliant services for the manufacturing and quality control of biologics, including cell and virus banks, viral vectors, and biosafety testing. Their innovation lies in integrating customized assay development with regulatory-grade production capabilities, supported by in-house BSL-2 and BSL-3 infrastructure. They offer end-to-end solutions from characterization to lot release, with long-term storage and analytical expertise. Positioned at the interface between R&D and industrial production, Clean Cells enables safe, traceable, and scalable biologic development for therapeutic applications.

# data[].attributes.attachment_link.title
Clean Cells | A cGMP expert for the safety of your biological products

# data[].attributes.attachment_link.description
Clean Cells is your reliable CMO/CRO for cell and virus banks manufacturing with a strong expertise in Quality Control Testing for all kind of Bioproducts from R&D to market and in compliance with worldwide regulatory agencies.

# data[].attributes.location_name
APILAB Biosurveillance par l'abeille, Rue Henri Bessemer, Lagord, France

# data[].attributes.body
Apilab is a French environmental biotech company specializing in bee-based biosurveillance. They deploy hives and insect hotels to collect pollen, propolis, and environmental debris, then analyze these samples to generate indicators of air quality, biodiversity, and ecosystem health. Their toolkit—combining in-field sampling with lab-grade analytics—provides near real-time, integrative metrics that reflect cumulative exposure, useful for companies, municipalities, and conservation efforts. The innovation lies in harnessing bee foraging behavior as an eco-sensor network: a scalable, biologically rooted method that complements traditional monitoring techniques with living data from the environment.

# data[].attributes.attachment_link.description
Expert en biosurveillance par l’abeille Apilab évalue la biodiversité et l’impact des activités humaines sur l’environnement et les pollinisateurs. --- Les abeilles sauvages et mellifères sont de véritables sentinelles de l’environnement. Elles collectent et bio-accumulent les éléments présents dans la nature. Apilab a créé une méthode qui permet d’obtenir des indicateurs scientifiques, facilement intégrables dans

# data[].attributes.location_name
Microbia Environnement, Pôle entrepreneurial, Rue des Sitelles, Argelès-sur-Mer, France

# data[].attributes.body
Microbia Environnement develops genetically encoded biosensors to detect and predict active microbial threats in water systems. Their proprietary CARLA technology monitors live microbial activity in near real-time, enabling early detection of contamination before it escalates. This anticipatory system outperforms traditional testing by offering rapid, precise alerts—letting water managers mitigate risks proactively rather than reactively. Ideal for utilities, aquaculture, and environmental monitoring, Microbia’s platform combines molecular microbiology and environmental science into a plug-and-play tool that safeguards water quality with foresight and accuracy.

# data[].attributes.custom_properties.0EAQISpI
Marine biology, microbiology, NGS , environnement

# data[].attributes.attachment_link.title
Microbia Environnement mesurer diagnostiquer la toxicité microbienne eau

# data[].attributes.attachment_link.description
Biocapteurs génétiques pour cibler les micro-organismes vivants et actifs susceptibles de proliférer et d’engendrer une toxicité de l’eau.

# data[].attributes.location_name
CoLabs Australia - Brunswick, Albert Street, Brunswick Victoria, Australie

# data[].attributes.body
Cortical Labs delivers the CL1, a compact “biological computer” that integrates lab-grown human neurons on silicon chips, enabling real-time stimulation, recording, and learning. Their platform supports live neural network experiments—such as playing Pong—while offering low-energy, ethical alternatives to animal testing. With built-in life support, six-month neuron viability, and remote cloud access, CL1 bridges neuroscience, AI, and drug discovery in a plug-and-play format. Innovation lies in harnessing actual human neuronal networks for computation and sensing—moving beyond dry models into authentic biologically driven processing.

# data[].attributes.attachment_link.readable_text
What comes next

We're not making smarter computers, more efficient data centers, or more personalised advertising. We're doing this to see what happens. What happens if we grow a mind native to the infinite possibility space of digital computing?

We wonder what it will mean for digital spaces, for robotics, science, personal care. To explore the delineation between the personal mind, the distributed mind, digital and physical realities. To blur those boundaries. We wonder what it means to grow a mind, born of the physical world, but a native of the digital world, where that mind will go, and what it will teach us.

Wonder with us.

# data[].attributes.attachment_link.description
Cortical Labs are the creators of the DishBrain, combining living brain cells with computing devices to create machines with biological intelligence.

# data[].attributes.location_name
Pherecydes Pharma, Avenue Gaston Roussel, Romainville, France

# data[].attributes.body
[renommee PHAXIAM, fermée janvier 2025]

Pherecydes Pharma (now known as Phaxiam Therapeutics) pioneers precision phage therapy to tackle antibiotic-resistant bacterial infections. Their innovation centers on rapid matching of custom bacteriophage cocktails to a patient’s specific pathogen (e.g., Staphylococcus aureus, Pseudomonas aeruginosa, E. coli) using high-throughput screening and GMP production. The platform has delivered promising compassionate-use results in bone, joint, burn, and bloodstream infections, and has entered Phase II trials (e.g., PhagoDAIR) for prosthetic joint infections. Production-ready since 2021, their phage library and manufacturing capabilities support modular, strain-specific treatments—offering a targeted, adaptive alternative to broad-spectrum antibiotics without relying on synthetic analogues.

# data[].attributes.body
Phagos develops a precision phage therapy platform that leverages bacteriophages to selectively target and eliminate pathogenic bacteria. Their innovation lies in combining high-throughput phage screening with AI-driven matching algorithms, allowing for rapid identification and optimization of phage cocktails tailored to specific bacterial strains. The approach enables responsive, narrow-spectrum antimicrobials that preserve microbiota and adapt to resistance evolution. Initially applied in animal health, the platform demonstrates scalability, speed, and ecological precision—positioning Phagos as a next-generation alternative to conventional antibiotics.

# data[].attributes.attachment_link.title
phagos – Unleash Bacteriophage Potential

# data[].attributes.body
FinalSpark pioneers “wetware” computing by cultivating human brain organoids on multi-electrode arrays as living bioprocessors. These neurospheres—grown from iPSC-derived neurons—are integrated into an automated Neuroplatform accessible remotely via API, enabling researchers to stimulate and record neural activity in real time. The innovation lies in creating energy-efficient, self-organizing biological networks capable of continuous learning and scalable growth—offering a radical alternative to silicon-based AI with orders-of-magnitude lower power consumption. The trade-off: dependency on their proprietary organoid platform and orbital, closed ecosystem—but for labs exploring organoid intelligence, it’s a pioneering, plug-and-play route into true biocomputing.

# data[].attributes.custom_properties.0EAQISpI
Cell culture, organoids, organ-on-chip, AI

# data[].attributes.attachment_link.description
After an intensive year of relentless research, we are thrilled to announce that FinalSpark’s Biological Neuroplatform BNP has advanced to the production stage, pushing the boundaries of what we thought possible in neurophysiology.

# data[].attributes.body
Theremia develops an AI-driven drug optimization platform that designs next-generation drug derivatives with improved efficacy and safety across diverse patient populations. Their innovation lies in combining explainable machine learning and causal inference applied to multi-scale clinical and real-world data, enabling targeted adjustments in dosage, formulation, or administration tailored to specific demographic or disease subgroups. This empowers more precise clinical trials and supports rational drug repurposing. The platform is designed for pragmatic integration into pharma development pipelines—offering scalable, interpretable insights while balancing efficacy and tolerability for population-specific needs.

# data[].attributes.attachment_link.description
AI-driven platform to design drug derivatives with improved efficacy and tolerability across diverse demographics.

# data[].attributes.location_name
Sweetech SAS, Avenue de Rangueil, Toulouse, France

# data[].attributes.body
Sweetech develops a biotechnological platform for the production of rare and complex oligosaccharides through precision fermentation. Their innovation lies in the ability to biosynthesize structurally defined sugars—difficult or impossible to obtain via chemical synthesis—with high purity and scalability. These functional oligosaccharides have applications in health, nutrition, cosmetics, and microbiome modulation. By enabling tailor-made sugar structures with biological activity, Sweetech positions itself as a key player in applied glycobiology, offering both catalogue molecules and custom development services.

# data[].attributes.attachment_link.title
Sweetech | Fabricant d’oligosaccharides | Accueil

# data[].attributes.attachment_link.description
Sweetech est une startup deeptech qui innove dans la production de sucres rares ayant des applications pour la santé. La commercialisation de ces molécules actives permettra à nos partenaires de développer de nouvelles applications nutraceutiques, cosmétiques et médicales. Notre activité s’appuie sur une technologie plateforme propriétaire alliant performance économique et production industrielle, dans le respect de notre environnement.

# data[].attributes.location_name
TreeFrog Therapeutics, Avenue Gustave Eiffel, Pessac

# data[].attributes.body
TreeFrog Therapeutics is one of those companies that makes you pause mid-scroll and go, “Wait, they’re doing what with stem cells?”

Their big idea is deceptively simple: take fragile, high-maintenance pluripotent stem cells, stick them in tiny alginate capsules, and gently swirl them in bioreactors. Voilà—massive expansion, better viability, and allegedly fewer angry cell deaths. It is like giving stem cells a spa day while tricking them into working overtime.

From a scientific standpoint, it is elegant. From an industrial one, it is a clever play on scalability—a word everyone in cell therapy likes to say, but few can make actually happen. TreeFrog thinks they can. And honestly, maybe they can. They are funded, fast-moving, and French, which never hurts in biotech PR.

# data[].attributes.attachment_link.title
TreeFrog Therapeutics I Thérapies cellulaires dérivées de cellules iPS I Thérapie cellulaire pour tous

# data[].attributes.attachment_link.description
TreeFrog Therapeutics vise à rendre les thérapies cellulaires dérivées des iPS plus sûres, plus efficaces et plus abordables afin de guérir des millions de patients.

# data[].attributes.body
Inorevia develops microfluidic automation platforms aimed at ultra-low volume sample prep for genomics and multi-omics applications. Their flagship device, Magelia, integrates magnetic bead handling and droplet-based reactions to enable high-efficiency protocols (e.g., RNA-seq, ChIP-seq) in nanoliter to microliter volumes.

Scientifically, the pitch is strong: reduced reagent use, improved reproducibility, and high sensitivity from minimal input material—ideal for clinical or rare samples.

# data[].attributes.attachment_link.readable_text
THE MAGELIA PLATFORM: An all-in-one game-changing solution

Magelia is a unique multi-OMICs platform, which harnesses our disruptive core technology for high precision magnetic bead handling in low volumes. Magelia outperforms manual protocols in terms of output quality, process efficiency, turnaround time and robustness. Its full integration drastically reduces the need for multiple lab equipments, integrating all the features required to perform most molecular biology protocols. Its full automation ensures high day-to-day reproducibility.

# data[].attributes.location_name
Life and Soft, Rue de la Redoute, Fontenay-aux-Roses

# data[].attributes.body
Life & Soft combines industrial-grade sequencing and bioinformatics under one roof. Since 2013, they’ve built the LifePipe® suite—with modules for variants, microbiome, and virology analysis—paired with NGS Manager®, an ISO 9001‑certified platform managing Illumina, Nanopore (GridION, P2 Solo), and 10X Chromium workflows at CEA Fontenay‑aux‑Roses . The science is solid: hands-off pipelines ensure reproducibility, minimize errors, and tackle low-input clinical or rare samples with confidence. In April 2025 SeqOne snapped them up to bulk up its multi‑omics muscle and reach international labs .

# data[].attributes.attachment_link.title
Services et Solutions en Bio-informatique - Life And Soft

# data[].attributes.attachment_link.description
Services et Solutions en Bio-informatique. Solution clé en main, du séquençage jusqu’à l’analyse bioinformatique.

# data[].attributes.location_name
Cherry Biotech, Rue de la Beaune, Montreuil

# data[].attributes.headline
Cherry Biotech, Rue de la Beaune, Montreuil

# data[].attributes.subject
Cherry Biotech, Rue de la Beaune, Montreuil

# data[].attributes.body
Cherry Biotech engineers precision tools for live-cell and 3D cultures. Their CherryTemp system uses dual‑Peltier liquid exchange to shift microscope-stage temperatures, ideal for fast thermal experiments on worms, cells or proteins . Their CubiX platform adds gas, flow and temperature control to standard multiwell plates for long-term perfusion studies in organoids and tissue chips. Scientifically, they offer real-time environmental manipulation with tight control—perfect for physiology, drug testing or immune-response work on skin- or liver-on-chip models .

# data[].attributes.attachment_link.title
Cherry Biotech: Pioneering 3D Cell Culture

# data[].attributes.attachment_link.description
Cherry Biotech: Pioneering 3D Cell Culture & Alternatives to Animal Testing to Revolutionize Pre-clinical Drug Testing.

# data[].attributes.location_name
Génopole, Rue Henri Auguste Desbruères, Évry-Courcouronnes

# data[].attributes.body
Gourmey is the Parisian Biotech of cultivated foie gras—brewing real duck liver in 5,000 L suspension bioreactors with zero scaffolds, serum or mega‑infrastructure. They developped a unique continuous stem‑cell culture technology adapted for the food industry to serve up high‑end, scalable protein.

# data[].attributes.attachment_link.readable_text
We combine culinary craftsmanship and cutting-edge innovation to create exceptional taste and texture, driving the dining experience to new heights. Join us in reimagining haute cuisine, where innovation, taste, and sustainability converge.

# data[].attributes.attachment_link.description
We create sustainable cultivated meat delights for an uncompromising and conscious generation.

# data[].attributes.location_name
Humacyte Global, Inc, North Carolina 54, Durham, Caroline du Nord, États-Unis

# data[].attributes.headline
Humacyte Global, Inc, North Carolina 54, Durham, Caroline du Nord, États-Unis

# data[].attributes.subject
Humacyte Global, Inc, North Carolina 54, Durham, Caroline du Nord, États-Unis

# data[].attributes.body
Humacyte develops off-the-shelf, bioengineered human vessels designed to integrate and remodel within the patient’s body. These vessels are bioengineered vascular grafts designed to mimic the structure and function of a native human blood vessel. Their Human Acellular Vessel (HAV) is manufactured from human smooth muscle cells cultured on a biodegradable scaffold, then decellularized to leave a durable, immunologically inert extracellular matrix. Once implanted, it becomes repopulated by the host’s own cells, effectively transforming into living tissue.

# data[].attributes.custom_properties.0EAQISpI
clinical, biotherapy, cell culture, 3D, matrix

# data[].attributes.attachment_link.title
Universally Implantable Regenerative Human Tissues - Humacyte Global, Inc.

# data[].attributes.location_name
Génopole, Rue Henri Auguste Desbruères, Évry-Courcouronnes

# data[].attributes.body
Nutropy is the French biotech of animal‑free cheese, using precision fermentation to brew milk proteins, caseins, and fats identical to those found in cow’s milk—minus the cow. They offer a “cheeseable milk” ingredients that lets dairy producers craft real-tasting cheese with sustainable flair and no animal welfare compromise. Founded in 2022, Nutropy blends deep biotech know-how with French culinary pride. Their industrial-scale fermentation process is designed for low resource use.

# data[].attributes.attachment_link.description
No animals involved, full cheese experience.

# data[].attributes.location_name
91 Rue du Faubourg Saint-Honoré, 75008 Paris

# data[].attributes.body
nextProtein is a Paris‑based biotech startup turning food waste into sustainable protein using Black Soldier Fly larvae. Their industrial process converts organic by-products into high‑value ingredients—protein powder, oil, and natural fertilizer—with far lower land use and carbon footprint than soy: just 100 m² yields as much protein as 100 ha of soy fields. Approved in the EU for aquaculture and expanding into poultry, pork, and pet-food markets, they now produce around 1 tonne of protein per day at a 2,500 m² facility in Tunisia. Founded in 2015, at one point, their R&D department was proudly hosted at SupBiotech—hinting at deep academic roots. A great opportunity to discover industrial circular‑economy.

# data[].attributes.attachment_link.description
nextProtein is developing a large scale and sustainable insect based source of protein. The bioconversion of fly larvae fed with organic waste generates valuable feed components for fish, livestock and pets.

# data[].attributes.location_name
CN Bio, Cambridge Science Park Milton Road, Milton, Cambridge, Royaume-Uni

# data[].attributes.headline
CN Bio, Cambridge Science Park Milton Road, Milton, Cambridge, Royaume-Uni

# data[].attributes.subject
CN Bio, Cambridge Science Park Milton Road, Milton, Cambridge, Royaume-Uni

# data[].attributes.body
CN Bio is a UK-based biotech specialist in organ-on-a-chip technology, offering the PhysioMimix® platform—a compact benchtop microphysiological system that accurately models human tissues (liver, lung, gut, and multi-organ combinations) under dynamic, perfused 3D conditions. Leveraging over a decade of academic pedigree (originating from MIT and Oxford), their system supports drug absorption, metabolism (ADME), toxicology (e.g., drug-induced liver injury), disease modeling (NASH, hepatitis B), and immune interaction studies. It is user-friendly, integrates seamlessly with standard lab incubators, allows multi-well scalability, and enables real-time sampling—all while delivering human-relevant, translatable data that reduces reliance on animal testing.

# data[].attributes.custom_properties.0EAQISpI
microfluidics, matrix, 3D, cel culture, organ-on-chip

# data[].attributes.attachment_link.description
We are a leading Organ-on-a-chip (OOC) company that has developed single- and multi-organ microphysiological systems (MPS) and assays that improve the accuracy and efficiency of drug discovery. Our PhysioMimix™ OOC lab-benchtop instruments, enable researchers to model human biology in the lab through rapid and predictive 3D human tissue-based studies that harness microfluidic technology. The technology bridges the gap between traditional cell culture and human studies, advancing towards the simulation of human biological conditions to support the accelerated development of new therapeutics. Our channel is designed to provide you with resources to learn more about OOC and its applications.

# data[].attributes.location_name
Orakl Oncology, Rue Gabriel Péri, Le Kremlin-Bicêtre

# data[].attributes.body
Orakl Oncology is a French tech‑bio startup developing an AI‑powered “tumor avatar” platform to accelerate and de‑risk oncology drug development. They generate patient-specific tumor organoids ("avatars") that replicate tumor heterogeneity, link them to clinical and omics data, and apply machine learning to predict drug responses, design combinations, and optimize patient trial matching. Their commercial offerings, O‑Predict and O‑Validate, forecast response rates and validate biological targets. Founded in 2023 as a Gustave Roussy spin‑out, Orakl has built both wet‑lab and computational pipelines. . Scientifically, the platform merges strong cellular biology with real‑world data and AI, offering scalable patient‑relevant models that outclass traditional animal or cell-line studies.

# data[].attributes.custom_properties.0EAQISpI
organ-on-chip, 3D, cell culture, clinical

# data[].attributes.location_name
801 West Baltimore Street, Baltimore, MD 21201, USA

# data[].attributes.body
Autica Bio is a U.S. biotechnology startup focused on developing precision, stem cell–derived brain organoid models to unveil the genetic and cellular underpinnings of autism spectrum conditions. By leveraging human induced pluripotent stem cells (hiPSCs) and serum-free embryoid bodies, they create diverse brain organoids that reflect patient-specific neurobiology. This enables high-throughput screening of biomarkers and candidate therapeutic compounds in a system mirroring early cortical development. Guided by a team of neurobiologists, geneticists, and cellular biologists, and backed by peer-reviewed research and grant support, Autica Bio aims to translate organoid-based insights into targeted autism treatments—addressing an area with significant unmet medical need and limited therapeutic options.

# data[].attributes.attachment_link.description
Autica Bio is at the forefront of autism research, using brain organoids to explore genetics and cellular behavior, pioneering breakthroughs for autism therapeutics. Discover innovative science for hope.